By Marie Rosenthal
ORLANDO, FLA.—Eravacycline (Xerava, Tetraphase Pharmaceuticals) was effective in treating patients with complicated intra-abdominal infections (cIAIs) who had characteristics that are associated with poor outcomes, according to a poster presented at the 2019 annual MAD-ID (Making a Difference in Infectious Diseases) meeting (poster 75E).
The researchers performed a pooled analysis of two multicenter, phase 3, randomized, double-blind, placebo-controlled clinical